Drug Profile
Research programme: hepatitis C therapeutics - Genelabs/Genovate Biotechnology/NHRI
Latest Information Update: 19 Apr 2011
Price :
$50
*
At a glance
- Originator Genelabs Technologies; Genovate Biotechnology; National Health Research Institutes
- Developer Genelabs Technologies; Genovate Biotechnology
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
- 24 Jul 2008 Early research in Hepatitis C in Taiwan (unspecified route)
- 24 Jul 2008 Early research in Hepatitis C in USA (unspecified route)